Monograph Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
RQ Bio
25 Jun 2026
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Elevara Medicines
22 Oct 2025
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
Monograph Capital
- 2(12 months)
- monograph.bio
- Update Information
More venture news
- 17 Sept 2026
MagenticMagentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers
Series ASupply Chain - 15 Sept 2026
Jack & JillJack & Jill unlocks £30m Series A led by Air Street Capital to run dual-agents on both sides of hiring market
Series AHR - 26 Aug 2026
Certain EnergyCertain Energy raises a £10m Series A led by British Business Bank for long-duration battery storage on the clean energy grid
Series AEnergy
